Clinical Trial Update: OZURDEX in Age Related Macular Degeneration as Adjunct to Ranibizumab [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating Ozurdex as an adjunct to ranibizumab for wet age-related macular degeneration has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• Lucentis (ranibizumab)
• Ozurdex (dexamethasone intravitreal implant)

Snippet

Sponsor: McMaster University | Conditions: Wet Macular Degeneration | Phase 2 | Status: COMPLETED